| Item Type | Name |
|
Concept
|
Diabetic Nephropathies
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy.
|
|
Academic Article
|
Comparative effects of different antihypertensive treatments on progression of diabetic renal disease.
|
|
Academic Article
|
Diabetic nephropathy. What you need to know to preserve kidney function.
|
|
Academic Article
|
Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists.
|
|
Academic Article
|
Hypertension in diabetic patients. An overview of interventional studies to preserve renal function.
|
|
Academic Article
|
Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
|
|
Academic Article
|
Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy.
|
|
Academic Article
|
Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction.
|
|
Academic Article
|
Socioeconomic impact of diabetic nephropathy: can we improve the outcome?
|
|
Academic Article
|
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
|
|
Academic Article
|
Renal mortality associated with non-insulin-dependent diabetes mellitus.
|
|
Academic Article
|
The renin-angiotensin system in diabetic nephropathy: the endothelial connection.
|
|
Academic Article
|
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.
|
|
Academic Article
|
Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.
|
|
Academic Article
|
Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management.
|
|
Academic Article
|
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
|
|
Academic Article
|
Risks for renal involvement in diabetes.
|
|
Academic Article
|
When to discontinue ACE inhibitors for nephropathy.
|
|
Academic Article
|
Diabetic hypertensive patients: improving their prognosis.
|
|
Academic Article
|
A practical approach to achieving recommended blood pressure goals in diabetic patients.
|
|
Academic Article
|
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
|
|
Academic Article
|
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
|
|
Academic Article
|
A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease.
|
|
Academic Article
|
The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
|
|
Academic Article
|
Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control.
|
|
Academic Article
|
Role for beta-blockers in the management of diabetic kidney disease.
|
|
Academic Article
|
Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches.
|
|
Academic Article
|
Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.
|
|
Academic Article
|
Hypertension and nephropathy.
|
|
Academic Article
|
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
|
|
Academic Article
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
|
Academic Article
|
Diabetes and chronic kidney disease: tragedy and challenge.
|
|
Academic Article
|
What have we learned from the current trials?
|
|
Academic Article
|
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
|
|
Academic Article
|
How to adjust ACE inhibitors and ARBs in diabetes?
|
|
Academic Article
|
Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.
|
|
Academic Article
|
Differential effects of calcium antagonist subclasses on markers of nephropathy progression.
|
|
Academic Article
|
The role of calcium antagonists in chronic kidney disease.
|
|
Academic Article
|
Blood pressure control and nephroprotection in diabetes.
|
|
Academic Article
|
Management of hypertension in the cardiometabolic syndrome and diabetes.
|
|
Academic Article
|
Treatment of hypertension in patients with renal disease.
|
|
Academic Article
|
Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program.
|
|
Academic Article
|
Clinical importance of microalbuminuria in diabetes and hypertension.
|
|
Academic Article
|
Effects of different calcium antagonists on proteinuria associated with diabetes mellitus.
|
|
Academic Article
|
Protein kinase C-beta inhibition: a promise not yet fulfilled.
|
|
Academic Article
|
The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states.
|
|
Academic Article
|
Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
|
|
Academic Article
|
Slowing the progression of diabetic nephropathy and its cardiovascular consequences.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented.
|
|
Academic Article
|
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease, a marriage that should be prevented.
|
|
Academic Article
|
Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?
|
|
Academic Article
|
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
|
|
Academic Article
|
The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented.
|
|
Academic Article
|
Novel therapies of diabetic nephropathy.
|
|
Academic Article
|
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
|
|
Academic Article
|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
|
|
Academic Article
|
Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
|
|
Academic Article
|
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
|
|
Academic Article
|
The pathogenesis of diabetic nephropathy.
|
|
Academic Article
|
Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Limitations of metformin use in patients with kidney disease: are they warranted?
|
|
Academic Article
|
Prehypertension: is it relevant for nephrologists?
|
|
Academic Article
|
Antihypertensive therapy and progression of diabetic renal disease.
|
|
Academic Article
|
Diabetic nephropathy.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
|
|
Academic Article
|
Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial.
|
|
Academic Article
|
Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs.
|
|
Academic Article
|
Do fibrates truly preserve kidney function?
|
|
Academic Article
|
Telmisartan in incipient and overt diabetic renal disease.
|
|
Academic Article
|
ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects.
|
|
Academic Article
|
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
|
|
Academic Article
|
Microalbuminuria in non-insulin-dependent diabetes mellitus. Implications for renal survival.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented.
|
|
Academic Article
|
The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented.
|
|
Academic Article
|
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).
|
|
Academic Article
|
Effects of angiotensin II receptor blockers on diabetic nephropathy.
|
|
Academic Article
|
Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy.
|
|
Academic Article
|
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.
|
|
Academic Article
|
Treatment of renal failure and blood pressure.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
|
|
Academic Article
|
ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.
|
|
Academic Article
|
Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans.
|
|
Academic Article
|
When to refer patients to a nephrologist?
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented.
|
|
Academic Article
|
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
|
|
Academic Article
|
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
|
|
Academic Article
|
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.
|
|
Academic Article
|
Diabetic kidney disease: a report from an ADA Consensus Conference.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Microalbuminuria as a risk predictor in diabetes: the continuing saga.
|
|
Academic Article
|
Diabetic kidney disease: a report from an ADA Consensus Conference.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
|
|
Academic Article
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
|
Academic Article
|
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
|
|
Academic Article
|
Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
|
|
Academic Article
|
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
|
|
Academic Article
|
Update on blood pressure goals in diabetes mellitus.
|
|
Academic Article
|
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
|
|
Academic Article
|
Hypertension Management in Diabetic Kidney Disease.
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply.
|
|
Academic Article
|
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
|
|
Academic Article
|
Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
|
|
Academic Article
|
Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy.
|
|
Academic Article
|
Baseline characteristics and enrichment results from the SONAR trial.
|
|
Academic Article
|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
|
|
Academic Article
|
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
|
|
Academic Article
|
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
|
|
Academic Article
|
SGLT2 Inhibitors and Mechanisms of Hypertension.
|
|
Academic Article
|
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes.
|
|
Academic Article
|
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not.
|
|
Academic Article
|
Novel therapies for diabetic kidney disease.
|
|
Academic Article
|
Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes.
|
|
Academic Article
|
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
|
|
Academic Article
|
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
|
|
Academic Article
|
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
|
|
Academic Article
|
Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician.
|
|
Academic Article
|
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
|
|
Academic Article
|
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
|
|
Academic Article
|
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
|
|
Academic Article
|
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
|
|
Academic Article
|
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
|
|
Academic Article
|
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
|
|
Academic Article
|
Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial.
|
|
Academic Article
|
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
|
|
Academic Article
|
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
|
|
Academic Article
|
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
|
|
Academic Article
|
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
|
|
Academic Article
|
Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial.
|
|
Academic Article
|
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design.
|
|
Academic Article
|
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
|
|
Academic Article
|
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
|
|
Academic Article
|
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
|
|
Academic Article
|
Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone.
|
|
Academic Article
|
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
|
|
Academic Article
|
A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial.
|
|
Academic Article
|
Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
|
|
Academic Article
|
Molecular mechanisms and therapeutic targets for diabetic kidney disease.
|
|
Academic Article
|
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
|
|
Academic Article
|
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
|
|
Academic Article
|
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.
|
|
Academic Article
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
|
|
Academic Article
|
Glucose-lowering treatment patterns in patients with diabetic kidney disease.
|
|
Academic Article
|
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
|
|
Academic Article
|
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
|
|
Academic Article
|
The changing trajectory of diabetic kidney disease.
|
|
Academic Article
|
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
|
|
Academic Article
|
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
|
|
Academic Article
|
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
|
|
Academic Article
|
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.
|
|
Academic Article
|
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression.
|
|
Academic Article
|
Slowing the Progression of Diabetic Kidney Disease.
|
|
Academic Article
|
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
|
|
Academic Article
|
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
|
|
Academic Article
|
The evolution of "pillars of therapy" to reduce heart failure risk and slow diabetic kidney disease progression.
|